The promise of novel direct oral anticoagulants

被引：22
作者：
Hoffman, Ron [1 ,2 ]
Brenner, Benjamin
机构：
[1] Rambam Hlth Care Campus, Dept Hematol & Bone Marrow Transplantat, In Patient Hematol Unit, IL-31096 Haifa, Israel
[2] Technion Israel Inst Technol, Bruce Rappaport Fac Med, In Patient Hematol Unit, IL-31096 Haifa, Israel
来源：
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY | 2012年 / 25卷 / 03期
关键词：
thromboembolism; new anticoagulants; direct thrombin inhibitors; factor Xa inhibitors; NONVALVULAR ATRIAL-FIBRILLATION; MOLECULAR-WEIGHT HEPARIN; DEEP-VEIN THROMBOSIS; VENOUS THROMBOEMBOLISM; DABIGATRAN ETEXILATE; DOUBLE-BLIND; ANTITHROMBOTIC THERAPY; STROKE PREVENTION; PREDICTING STROKE; KNEE REPLACEMENT;
D O I：
10.1016/j.beha.2012.06.004
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
The standard effective treatment of venous and arterial thromboembolism includes unfractionated and low-molecular weight heparin as well as warfarin, which have major disadvantages. In recent years, new anticoagulants have been developed in an attempt to overcome the known limitations of established treatment and develop improved therapies. This chapter reviews pharmacological properties of the new anticoagulants, the most recent trials assessing their safety and efficacy as well as potential advantages and disadvantages of using these novel drugs in real life. (c) 2012 Elsevier Ltd. All rights reserved.
引用
收藏
页码：351 / 360
页数：10
相关论文
共 65 条
  • [1] Albers GW, 2005, JAMA-J AM MED ASSOC, V293, P690
  • [2] Albers GW, 2003, LANCET, V362, P1691
  • [3] Apixaban with Antiplatelet Therapy after Acute Coronary Syndrome
    Alexander, John H.
    Lopes, Renato D.
    James, Stefan
    Kilaru, Rakhi
    He, Yaohua
    Mohan, Puneet
    Bhatt, Deepak L.
    Goodman, Shaun
    Verheugt, Freek W.
    Flather, Marcus
    Huber, Kurt
    Liaw, Danny
    Husted, Steen E.
    Lopez-Sendon, Jose
    De Caterina, Raffaele
    Jansky, Petr
    Darius, Harald
    Vinereanu, Dragos
    Cornel, Jan H.
    Cools, Frank
    Atar, Dan
    Luis Leiva-Pons, Jose
    Keltai, Matyas
    Ogawa, Hisao
    Pais, Prem
    Parkhomenko, Alexander
    Ruzyllo, Witold
    Diaz, Rafael
    White, Harvey
    Ruda, Mikhail
    Geraldes, Margarida
    Lawrence, Jack
    Harrington, Robert A.
    Wallentin, Lars
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2011, 365 (08) : 699 - 708
  • [4] [Anonymous], 2006, MANAG CARE INTERFACE
  • [5] Pharmacology and management of the vitamin K antagonists
    Ansell, Jack
    Hirsh, Jack
    Hylek, Elaine
    Jacobson, Alan
    Crowther, Mark
    Palareti, Gualtiero
    [J]. CHEST, 2008, 133 (06) : 160S - 198S
  • [6] Arepally Gowthami, 2010, Crit Pathw Cardiol, V9, P41, DOI 10.1097/HPC.0b013e3181d24562
  • [7] BARRITT DW, 1960, LANCET, V1, P1309
  • [8] Recent progress in anticoagulant therapy: oral direct inhibitors of thrombin and factor Xa
    Bauer, K. A.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 12 - 19
  • [9] Oral Rivaroxaban for Symptomatic Venous Thromboembolism.
    Bauersachs, Rupert
    Berkowitz, Scott D.
    Brenner, Benjamin
    Buller, Harry R.
    Decousus, Herve
    Gallus, Alex S.
    Lensing, Anthonie W.
    Misselwitz, Frank
    Prins, Martin H.
    Raskob, Gary E.
    Segers, Annelise
    Verhamme, Peter
    Wells, Phil
    Agnelli, Giancarlo
    Bounameaux, Henri
    Cohen, Alexander
    Davidson, Bruce L.
    Piovella, Franco
    Schellong, Sebastian
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (26) : 2499 - 2510
  • [10] Emerging options in the treatment of deep vein thrombosis and pulmonary embolism
    Brenner, Benjamin
    Hoffman, Ron
    [J]. BLOOD REVIEWS, 2011, 25 (05) : 215 - 221
1234567